Active, not recruitingNot applicableNCT06983665

Human Bioequivalence Study of Liposomal Amphotericin B for Injection

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Principal Investigator
Qing Wen
Jinan Central Hospital
Intervention
Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)(drug)
Enrollment
42 enrolled
Eligibility
18-55 years · All sexes
Timeline
2025 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06983665 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials